13 Assessing Intratumor Heterogeneity in Programmed Death-Ligand 1 (PD-L1) Protein Expression in Early-Stage Breast Cancer

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement39th Annual Miami Breast Cancer Conference® - Abstracts
Volume 36
Issue suppl 3
Pages: 14

Background

Programmed death–ligand 1 (PD-L1) expression is required for benefit from immune checkpoint inhibitors in metastatic triple-negative breast cancer (TNBC), although in the neoadjuvant setting, patients benefited regardless of PD-L1 expression. We aimed to examine intratumor spatial heterogeneity of PD-L1 protein expression in multiple regions of primary breast cancers.


Materials and Methods

Biopsies were collected from 3 separate tumor regions of surgically resected primary tumors without prior neoadjuvant systemic therapy. E1L3N antibody was used to assess PD-L1 status. The combined positivity score (CPS) method was used for scoring (PD-L1 positive defined as CPS >10). Fleiss Multirater Kappa assessed heterogeneity of PD-L1 expression among the different samples of the same tumor. Optimal agreement is suggested by a kappa agreement coefficient of 0.6 or more. Association between PD-L1 status and tumor-infiltrating lymphocyte (TIL) counts was assessed using Mann-Whitney test.


Results

Of the 33 included patients, 9 (27%) had TNBC, 5 (15%) had HER2-positive disease, and 19 (58%) had hormone receptor–positive, HER2-negative disease. Four of 33 patients (12%) had 1 biopsy sample showing PD-L1 positive status with additional biopsies of different regions of the tumor showing negative results. Fleiss’ kappa analysis on patients with all 3 biopsies per tumor available and able to be stained for PD-L1 (29 of 33 [88%]) showed an overall agreement of –0.36 (95% CI, –0.246 to 0.174; P = .739) when using CPS as categorical variable (positive vs negative) and 0.410 (95% CI, 0.286-0.535; P <.01) when using CPS as continuous variable. PD-L1 status was associated with TIL counts, with a median TIL count of 5% for PD-L1 positive and 0% for PD-L1 negative (P = .2949).


Conclusions

Our study showed that in 12% of the cases, PD-L1 was found to be positive in one of the tumor areas and all remaining biopsy samples of the same tumor were found to be negative, suggesting intratumor spatial heterogeneity regarding PD-L1 expression in early-stage breast cancer. However, due to the overall low incidence of PD-L1 positivity, it seems unlikely that the benefit of immunotherapy in early-stage breast cancer would be simply explained by sampling error. Further studies are required to investigate effective predictive biomarkers of response to immunotherapy, as well as to standardize PD-L1 assessment in breast cancer.

Author Affiliations:

Adriana Matutino Kahn,1 Reza Golestani,2 Malini Harigopal,2 Lajos Pusztai1

1Section of Medical Oncology, Yale School of Medicine, New Haven, CT

2Department of Pathology, Yale School of Medicine, New Haven, CT

Articles in this issue

15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients  in a Breast Cancer Registry
15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients in a Breast Cancer Registry
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy  and Symptoms
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
Related Content